{
    "clinical_study": {
        "@rank": "97380", 
        "acronym": "FIL_VERAL12", 
        "arm_group": [
            {
                "arm_group_label": "R-DHAP", 
                "arm_group_type": "Active Comparator", 
                "description": "R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + R-DHAP x 2, restaging with PET evaluation"
            }, 
            {
                "arm_group_label": "BR-DHAP", 
                "arm_group_type": "Experimental", 
                "description": "Bortezomib + R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + Bortezomib + R-DHAP x 2, restaging with PET evaluation"
            }
        ], 
        "brief_summary": {
            "textblock": "The probability to achieve CR with R-chemotherapy in patients failing a rituximab containing\n      first line regimen is quite low, in particular in cases with non GCB profile. The bioCORAL\n      trial suggest that ABC subset have a  dismal outcome whichever the induction treatment. Thus\n      it can be argued the addition of new molecule to the RDHAP regimen could be of value.\n      Bortezomib appears the best candidate in this setting as ABC subtypes constitutively express\n       NFkb, which is the target of bortezomib itself. Data from the literature suggest an\n      encouraging activity of R-chemo+ bortezomib in non GCB-derived DLBCL, although in small\n      series. Thus, the addition of bortezomib is here justified by the need to circumvent\n      constitutional resistance to chemotherapy. Published experience of the association between\n      bortezomib and cytarabine are also encouraging with acceptable cumulative toxicity."
        }, 
        "brief_title": "Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory DLBCL Patients Before High-Dose Chemotherapy BEAM With ASCT.", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diffuse Large B-cell Lymphoma Refractory", 
            "Diffuse Large B-cell Lymphoma Recurrent"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, multicenter, two-arm randomized phase II screening trial34 in young\n      patients (18-65 years) affected by relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL)\n      at diagnosis, eligible to high-dose therapy.\n\n      Aim of the study is to to assess whether the addition of Bortezomib to R-DHAP is more\n      promising than standard R-DHAP, as induction therapy before high dose chemotherapy with ASCT\n      with respect to response and safety. Patients will be randomized at first relapse between:\n      a) the standard salvage therapy Rituximab in association to DHAP every 28 days (R-DHAP) for\n      4 cycles and b) Bortezomib in association to the same regimen (BR-DHAP). In both arms the\n      induction therapy is followed by autologous stem cell transplantation or, if indicated, by\n      allogeneic stem cell transplant.\n\n      A patient is considered evaluable if it is possible to assess response by  PET after 4 cycle\n      or, if a patient withdraws from the study for PD, before completion of study treatment.\n\n      After providing written informed consent, patients will be evaluated for eligibility during\n      a 21-day screening period. If they continue to meet eligibility criteria, they will be\n      randomized to receive the first dose of BR-DHAP  or R-DHAP ."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 18-65\n\n          2. Relapsed/refractory disease after receiving one line of standard R-CHOP like\n             chemotherapy\n\n          3. Diffuse Large B-cell Lymphoma at relapse. Patient has to be re-biopsied prior to\n             study entry. If this is harmful for the patient, the patient can be enrolled if\n             archival tumor sample and block from first diagnosis are available.\n\n          4. No prior Bortezomib therapy\n\n          5. Measurable and/or evaluable disease\n\n          6. Any Ann Arbor stage and IPI group at relapse\n\n          7. Performance status < 2 according to ECOG scale unless due to lymphoma\n\n          8. No Central Nervous System (CNS) disease (meningeal and/or brain involvement by\n             lymphoma)\n\n          9. Adequate haematological counts: ANC > 1.5 x 109/L, Hgb > 10.5 g/dl (transfusion\n             independent), Platelet count > 75 x 109/L (transfusion independent), with the\n             exception of cytopenia due to lymphoma bone marrow involvement\n\n         10. HIV negativity, HCV negativity, HBV negativity or patients with HBcAb +, HBsAg -, HBs\n             Ab+/- with HBV-DNA negativity (in these patients Lamivudine prophylaxis is mandatory)\n\n         11. Normal liver function (ALP, AST, ALT, GGT, conjugated bilirubin total < 2 x ULN) if\n             not related to lymphoma\n\n         12. Normal kidney function (creatinine clearance > 45 ml/min)\n\n         13. Cardiac ejection fraction > 50% (MUGA scan or echocardiography)\n\n         14. Normal lung function\n\n         15. Absence of active opportunistic infections\n\n         16. Non peripheral neuropathy or active neurological non neoplastic disease of CNS\n\n         17. Non major surgical intervention prior 3 months to randomization if not due to\n             lymphoma and/or no other disease life-threatening that can compromise chemotherapy\n             treatment\n\n         18. Disease free of prior malignancies other than lymphoma for > 3 years with exception\n             of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma\n             in situ of the cervix or breast\n\n         19. Life expectancy > 6 months\n\n         20. No psychiatric illness that precludes understanding concepts of the trial or signing\n             informed consent\n\n         21. Written informed consent\n\n         22. Women must be:\n\n               -  postmenopausal for at least 1 year (must not have had a natural menses for at\n                  least 12 months)\n\n               -  surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal\n                  ligation, or otherwise be incapable of pregnancy),\n\n               -  abstinent (at the discretion of the investigator/per local regulations), or\n\n               -  if sexually active, be practicing a highly effective method of birth control\n                  (eg, prescription oral contraceptives, contraceptive injections, contraceptive\n                  patch, intrauterine device, double-barrier method (eg, condoms, diaphragm, or\n                  cervical cap, with spermicidal foam, cream, or gel, male partner sterilization)\n                  as local regulations permit, before entry, and must agree to continue to use the\n                  same method of contraception throughout the study. They must also be prepared to\n                  continue birth control measures for at least 12 months after terminating\n                  treatment.\n\n         23. Women of childbearing potential must have a negative serum or urine beta-human\n             chorionic gonadotropin (beta-hCG) pregnancy test at screening\n\n         24. Men must agree to use an acceptable method of contraception (for themselves or female\n             partners as listed above) for the duration of the study. Men must agree to use a\n             double barrier method of birth control and to not donate sperm during the study and\n             for 3 months after receiving the last dose of study drug.\n\n        Exclusion Criteria:\n\n          1. Diagnosis of Lymphoblastic Lymphoma, Burkitt Lymphoma, Non Hodgkin Lymphoma CD20\n             negative, Mantle Cell Lymphoma, Follicular Lymphoma g I-II-IIIa-IIIb, Primary\n             Mediastinal Lymphoma\n\n          2. Age > 65 years\n\n          3. Patients ineligible to high-dose chemotherapy\n\n          4. Performance status > 2 according to ECOG scale if not due to lymphoma\n\n          5. Patient has known or suspected hypersensitivity or intolerance to Rituximab\n\n          6. Patient has  received an experimental drug or used an experimental medical device\n             within 4 weeks before the planned start of treatment. Concurrent participation in\n             non-treatment studies is allowed, if it will not interfere with participation in this\n             study.\n\n          7. CNS disease (meningeal and/or brain involvement by lymphoma)\n\n          8. History of clinically relevant liver or renal insufficiency; significant cardiac,\n             vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic,\n             hematologic, psychiatric, or metabolic disturbances\n\n          9. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable\n             dose for at least 3 months before first dose of study drug\n\n         10. Uncontrolled or severe cardiovascular disease including myocardial infarction within\n             six months of enrollment, New York Heart Association (NYHA) Class III or IV heart\n             failure, uncontrolled angina, clinically significant pericardial disease, or cardiac\n             amyloidosis\n\n         11. Cardiac ejection fraction < 45% (MUGA scan or echocardiography)\n\n         12. Creatinine clearance < 45 ml/min\n\n         13. Presence of major neurological disorders\n\n         14. HIV positivity, HCV positivity, HBV positivity with the exception of patients with\n             HBcAb +, HbsAg -, HBs Ab+/- with HBV-DNA negative\n\n         15. Active opportunistic infection\n\n         16. Major surgical intervention prior 3 months to randomization if not due to lymphoma\n             and/or other disease life-threatening that can compromise chemotherapy treatment\n\n         17. Prior malignancies other than lymphoma in the last 3 years with exception of\n             currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in\n             situ of the cervix or breast\n\n         18. Life expectancy < 6 months\n\n         19. Any other coexisting medical or psychological condition that would preclude\n             participation in the study or compromise ability to give informed consent.\n\n         20. If female, the patient is pregnant or breast-feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "108", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805557", 
            "org_study_id": "FIL_VERAL12"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "R-DHAP", 
                    "BR-DHAP"
                ], 
                "description": "Rituximab 375 mg/sqm iv day 0 or 1\nCisplatin 100 mg/sqm iv day 1 in 6-hours infusion\nCytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3\nDexamethasone 40 mg day 1-4\nPegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)\nRituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy", 
                "intervention_name": "R-DHAP", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BR-DHAP", 
                "description": "Rituximab 375 mg/sqm iv day 0 or 1\nBortezomib SC 1.5 mg/sqm day 1, day 4\nCisplatin 100 mg/sqm iv day 1 in 6-hours infusion\nCytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3\nDexamethasone 40 mg day 1-4\nPegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)\nRituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will  be repeated every 28 days.", 
                "intervention_name": "BR-DHAP", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bortezomib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diffuse Large B-cell Lymphoma (DLBCL)", 
            "Bortezomib"
        ], 
        "lastchanged_date": "March 5, 2013", 
        "location": [
            {
                "contact": {
                    "email": "luigirigacci@unifi.it; benedettapuccini@virgilio.it", 
                    "last_name": "Luigi Rigacci", 
                    "phone": "+39 055-7947358"
                }, 
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy", 
                        "state": "FI", 
                        "zip": "50134"
                    }, 
                    "name": "AOU Careggi"
                }, 
                "investigator": {
                    "last_name": "Luigi Rigacci, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "chiara.rusconi@ospedaleniguarda.it", 
                    "last_name": "Chiara Rusconi, MD", 
                    "phone": "+39 02 - 64442668"
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20162"
                    }, 
                    "name": "A.O. Niguarda"
                }, 
                "investigator": {
                    "last_name": "Chiara Rusconi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "enrico.pogliani@unimib.it; marziaborsetto@yahoo.it", 
                    "last_name": "Enrico Pogliani, MD", 
                    "phone": "039-2339435"
                }, 
                "facility": {
                    "address": {
                        "city": "Monza", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20052"
                    }, 
                    "name": "Osp. San Gerardo"
                }, 
                "investigator": {
                    "last_name": "Enrico Pogliani, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "d.vallisa@auslpc.it", 
                    "last_name": "Daniele Vallisa, MD", 
                    "phone": "+39 0523-303701/719"
                }, 
                "facility": {
                    "address": {
                        "city": "Piacenza", 
                        "country": "Italy", 
                        "state": "PC", 
                        "zip": "29121"
                    }, 
                    "name": "Ospedale Civile Guglielmo da Saliceto"
                }, 
                "investigator": {
                    "last_name": "Daniele Vallisa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mmichieli@cro.it", 
                    "last_name": "Mariagrazia Michieli, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Aviano", 
                        "country": "Italy", 
                        "state": "Pordenone", 
                        "zip": "33081"
                    }, 
                    "name": "CRO Aviano"
                }, 
                "investigator": {
                    "last_name": "Mariagrazia Michieli, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "medint.nocera@libero.it", 
                    "last_name": "Alfonso M. D'Arco, MD", 
                    "phone": "+39 081-9213370"
                }, 
                "facility": {
                    "address": {
                        "city": "Nocera Inferiore", 
                        "country": "Italy", 
                        "state": "SA", 
                        "zip": "84014"
                    }, 
                    "name": "Osp. Umberto I"
                }, 
                "investigator": {
                    "last_name": "Alfonso M. D'Arco, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "giuseppe.saglio@unito.it", 
                    "last_name": "Giuseppe Saglio, Prof.", 
                    "phone": "00390119026721"
                }, 
                "facility": {
                    "address": {
                        "city": "Orbassano", 
                        "country": "Italy", 
                        "state": "Torino", 
                        "zip": "10043"
                    }, 
                    "name": "Medicina Interna 2 ad indirizzo Ematologico AOU San Luigi Gonzaga"
                }, 
                "investigator": {
                    "last_name": "Giuseppe Saglio, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "marco.ladetto@unito.it;antonella.fiorillo@yahoo.it", 
                    "last_name": "Marco Ladetto, MD", 
                    "phone": "+39 011-6334264"
                }, 
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "state": "TO", 
                        "zip": "10126"
                    }, 
                    "name": "AOU San Giovanni Battista-Ematologia 1"
                }, 
                "investigator": {
                    "last_name": "Marco Ladetto, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "zaja.francesco@aoud.sanita.fvg.it;d'odorico.cristina@aoud.sanita.fvg.it", 
                    "last_name": "Francesco Zaja, MD", 
                    "phone": "+39 0432-559662"
                }, 
                "facility": {
                    "address": {
                        "city": "Udine", 
                        "country": "Italy", 
                        "state": "UD", 
                        "zip": "33100"
                    }, 
                    "name": "Azienda Ospedaliero - Universitaria di Udine"
                }, 
                "investigator": {
                    "last_name": "Francesco Zaja, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gallarate", 
                        "country": "Italy", 
                        "state": "Varese"
                    }, 
                    "name": "Osp. S. Antonio Abate Gallarate"
                }, 
                "investigator": {
                    "last_name": "Fabrizio Ciambelli, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "francesco.passamonti@ospedale.varese.it", 
                    "last_name": "Francesco Passamonti", 
                    "phone": "+39 0332-393648"
                }, 
                "facility": {
                    "address": {
                        "city": "Varese", 
                        "country": "Italy", 
                        "state": "VA", 
                        "zip": "21100"
                    }, 
                    "name": "Ospedale di Circolo e Fondazione Macchi - Ematologia"
                }, 
                "investigator": {
                    "last_name": "Francesco Passamonti, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "segreteria@filinf.it", 
                    "last_name": "Flavia Salvi, MD", 
                    "phone": "+39 0131206294"
                }, 
                "facility": {
                    "address": {
                        "city": "Alessandria", 
                        "country": "Italy", 
                        "zip": "15121"
                    }, 
                    "name": "A.O. SS. Antonio e Biagio e C. Arrigo"
                }, 
                "investigator": {
                    "last_name": "Flavia Salvi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "g.gini@ospedaliriuniti.marche.it", 
                    "last_name": "Guido Gini, M.D", 
                    "phone": "00390713580384"
                }, 
                "facility": {
                    "address": {
                        "city": "Ancona", 
                        "country": "Italy", 
                        "zip": "60100"
                    }, 
                    "name": "Clinica di ematologia AOU Umberto I Ospedali Riuniti"
                }, 
                "investigator": {
                    "last_name": "Guido Gini, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brescia", 
                        "country": "Italy"
                    }, 
                    "name": "Divisione di Ematologia Spedali Civili"
                }, 
                "investigator": {
                    "last_name": "Alessandra Tucci, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brindisi", 
                        "country": "Italy"
                    }, 
                    "name": "Presidio Ospedaliero A.Perrino - Divisione di Ematologia"
                }, 
                "investigator": {
                    "last_name": "Gianni Quarta, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cagliari", 
                        "country": "Italy"
                    }, 
                    "name": "Divisione di Ematologia Osp. Businco"
                }, 
                "investigator": {
                    "last_name": "Giuseppina Cabras, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cagliari", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Roberto Binaghi"
                }, 
                "investigator": {
                    "last_name": "Giorgio La Nasa, DM", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Campobasso", 
                        "country": "Italy"
                    }, 
                    "name": "Universit\u00e0 Cattolica Campobasso"
                }, 
                "investigator": {
                    "last_name": "Sergio Storti, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Foggia", 
                        "country": "Italy"
                    }, 
                    "name": "A.O. Universitaria Ospedali Riuniti di Foggia"
                }, 
                "investigator": {
                    "last_name": "Silvana Capalbo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Universitaria San Martino"
                }, 
                "investigator": {
                    "last_name": "Marco Gobbi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "zip": "16132"
                    }, 
                    "name": "Ematologia 1 Ospedale S. Martino"
                }, 
                "investigator": {
                    "last_name": "Angelo Michele Carella, PROF", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Latina", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Santa Maria Goretti"
                }, 
                "investigator": {
                    "last_name": "Angelo De Blasio, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lecce", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Vito Fazzi"
                }, 
                "investigator": {
                    "last_name": "Nicola Di Renzo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "paolo.corradini@unimi.it", 
                    "last_name": "Paolo Corradini, Prof.", 
                    "phone": "00390223902950"
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20133"
                    }, 
                    "name": "SC Ematologia \u2010 Trapianto di midollo osseo Fond. IRCCS Istituto Nazionale Tumori"
                }, 
                "investigator": {
                    "last_name": "Paolo Corradini, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Maggiore IRCCS-Dipartimento di Ematologia"
                }, 
                "investigator": {
                    "last_name": "Luca Baldini, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy"
                    }, 
                    "name": "AORN Cardarelli U.O.Ematologia"
                }, 
                "investigator": {
                    "last_name": "Vincenzo Mettivier, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gianluca Gaidano, Prof.", 
                    "phone": "00390321660663"
                }, 
                "facility": {
                    "address": {
                        "city": "Novara", 
                        "country": "Italy", 
                        "zip": "28100"
                    }, 
                    "name": "SCDU Ematologia \u2010 Universit\u00e0 del Piemonte Orientale"
                }, 
                "investigator": {
                    "last_name": "Gianluca Gaidano, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "g.semenzato@unipd.it", 
                    "last_name": "Giampiero Semenzato, Prof.", 
                    "phone": "00390498212298"
                }, 
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "zip": "35100"
                    }, 
                    "name": "Ematologia e Immunologia Clinica, Dipartimento di Medicina Universit\u00e0 di Padova"
                }, 
                "investigator": {
                    "last_name": "Giampiero Semenzato, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale S. Antonio"
                }, 
                "investigator": {
                    "last_name": "Dario Marino, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mamusso@libero.it", 
                    "last_name": "Maurizio Musso, M.D.", 
                    "phone": "00390916806801"
                }, 
                "facility": {
                    "address": {
                        "city": "Palermo", 
                        "country": "Italy", 
                        "zip": "90146"
                    }, 
                    "name": "Oncoematologia Dipartimento oncologico La Maddalena"
                }, 
                "investigator": {
                    "last_name": "Maurizio Musso, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "franco.aversa@unipr.it", 
                    "last_name": "Franco Aversa, Prof.", 
                    "phone": "00390521903263"
                }, 
                "facility": {
                    "address": {
                        "city": "Parma", 
                        "country": "Italy", 
                        "zip": "43100"
                    }, 
                    "name": "U.O. Complessa di Ematologia Ospedale di Parma"
                }, 
                "investigator": {
                    "last_name": "Franco Aversa, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy"
                    }, 
                    "name": "Fond. Maugeri - Centro medico"
                }, 
                "investigator": {
                    "last_name": "Vittorio Fregoni, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ravenna", 
                        "country": "Italy"
                    }, 
                    "name": "Osp. S. Maria delle Croci"
                }, 
                "investigator": {
                    "last_name": "Alfonso Zaccaria, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reggio Calabria", 
                        "country": "Italy"
                    }, 
                    "name": "AO Bianchi Melacrino Morelli UO Ematologia"
                }, 
                "investigator": {
                    "last_name": "Caterina Stelitano, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reggio Emilia", 
                        "country": "Italy"
                    }, 
                    "name": "AO Arcispedale S.Maria Nuova Ematologia"
                }, 
                "investigator": {
                    "last_name": "Francesco Merli, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rimini", 
                        "country": "Italy"
                    }, 
                    "name": "Osp. degli Infermi Divisione di Oncologia"
                }, 
                "investigator": {
                    "last_name": "Annalisa Molinari, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rionero in Vulture (PZ)", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Oncologico regionale CROB"
                }, 
                "investigator": {
                    "last_name": "Pellegrino Musto, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "A.O. Universitaria S. Andrea"
                }, 
                "investigator": {
                    "last_name": "Maria Cristina, Cox", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rbattistini@scamilloforlanini.rm.it", 
                    "last_name": "Roberta Battistini, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "zip": "00149"
                    }, 
                    "name": "Ematologia Ospedale S.Camillo Forlanini"
                }, 
                "investigator": {
                    "last_name": "Roberta Battistini, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Osp.Sant'Eugenio Divisione di Ematologia"
                }, 
                "investigator": {
                    "last_name": "Elisabetta Abruzzese, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Universita' La Sapienza"
                }, 
                "investigator": {
                    "last_name": "Maurizio Martelli, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Policlinico Universitario Tor Vergata"
                }, 
                "investigator": {
                    "last_name": "Maria Cantonetti, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rozzano (MI)", 
                        "country": "Italy"
                    }, 
                    "name": "Clinica Humanitas"
                }, 
                "investigator": {
                    "last_name": "Balzarotti Monica, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Siena", 
                        "country": "Italy"
                    }, 
                    "name": "Policlinico Le Scotte Clinica Ematologica"
                }, 
                "investigator": {
                    "last_name": "Alberto Fabbri, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "marinal@unipg.it", 
                    "last_name": "Anna Marina Liberati, Prof", 
                    "phone": "0744/205971"
                }, 
                "facility": {
                    "address": {
                        "city": "Terni", 
                        "country": "Italy", 
                        "zip": "05100"
                    }, 
                    "name": "SC Oncoematologia con autotrapianto AO Santa Maria"
                }, 
                "investigator": {
                    "last_name": "Anna Marina Liberati, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy"
                    }, 
                    "name": "Osp. San Giovanni Battista_Molinette Ematologia 2"
                }, 
                "investigator": {
                    "last_name": "Umberto Vitolo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Trani", 
                        "country": "Italy"
                    }, 
                    "name": "Divisione di Ematologia Ospedale S. Nicola"
                }, 
                "investigator": {
                    "last_name": "Gaetano De Santis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Before High-Dose Chemotherapy BEAM With Autologous Stem Cell Transplantation (ASCT).", 
        "overall_contact": {
            "email": "segreteria@filinf.it", 
            "last_name": "Marco Calabrese, PhD", 
            "phone": "+390131206261"
        }, 
        "overall_contact_backup": {
            "email": "segreteria@filinf.it", 
            "last_name": "Sonia Perticone, PhD", 
            "phone": "+390131206071"
        }, 
        "overall_official": {
            "affiliation": "S.C. Ematologia 2 - Azienda Ospedaliera Citt\u00e0 della Salute e della Sienza - Presidio Molinette", 
            "last_name": "Umberto Vitolo, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of CR according to the Cheson 2007 response criteria, evaluated by PET scan", 
            "measure": "Complete Response (CR) Rate", 
            "safety_issue": "No", 
            "time_frame": "At the end of the induction phase (6 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805557"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "ORR at the end of the induction treatment is defined as Complete  Response (CR) or Partial Response according to the Cheson 2007 response criteria, evaluated by PET scan", 
                "measure": "Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "At the end of the induction phase (6 months)"
            }, 
            {
                "description": "OS will be defined as the time between the date of randomization and the date of death from any cause", 
                "measure": "Overall Survival (OS", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Incidence of grade 3 or higher Toxicity measured by CTCAE v.4 during therapy", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "amount of CD34+ stem cell collected/Kg", 
                "measure": "Mobilizing potential", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Proportion of randomized patients successfully completing ASCT", 
                "measure": "Feasibility", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Fondazione Italiana Linfomi ONLUS", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Janssen Pharmaceutica", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Janssen-Cilag Ltd.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica  Piemonte", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Fondazione Italiana Linfomi ONLUS", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}